Anti-Rabies Serum Market Report 2026

The anti-rabies serum market size has grown strongly in recent years. It will grow from $1.5 billion in 2025 to $1.58 billion in 2026 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to increasing incidence of rabies exposure cases, expansion of hospital-based emergency treatment protocols, availability of equine-derived immunoglobulins, government-supported rabies control programs, rising awareness of post-exposure prophylaxis.

The anti-rabies serum market size is expected to see strong growth in the next few years. It will grow to $1.95 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to increasing adoption of human anti-rabies immunoglobulin, expansion of rabies prevention initiatives in developing regions, rising investments in biologics manufacturing, growing focus on safer serum alternatives, strengthening public health vaccination frameworks. Major trends in the forecast period include increasing adoption of human-derived immunoglobulins, rising preference for prefilled syringe formats, expansion of cold-chain optimized serum distribution, growing focus on high-purity antibody formulations, improved standardization of post-exposure prophylaxis protocols.

The rising prevalence of dog bites is expected to drive the growth of the anti-rabies serum market. Dog bites refer to injuries caused when a dog bites or scratches a person, with severity ranging from minor to severe. These bites can lead to infections, significant wounds, and in some cases, the transmission of diseases such as rabies. Effective prevention and prompt medical treatment are crucial to managing the risks associated with dog bites. Factors such as increased urbanization, leading to more frequent interactions between people and dogs, a higher number of unrestrained or poorly trained dogs, and insufficient awareness about dog behavior and bite prevention, are contributing to the rising prevalence of dog bites. This has resulted in an increased demand for anti-rabies serum, as timely administration of the serum is essential for preventing rabies in individuals exposed to potentially infected animals. For example, in 2023, according to the American Veterinary Medical Association, the average cost of dog bite insurance claims was $58,545, with insurers paying out $1.12 billion in liability claims related to dog bites and other dog-related injuries. Dog bite claims rose by nearly 10% in 2023. As such, the rising incidence of dog bites is driving growth in the anti-rabies serum market.

Leading companies in the anti-rabies serum market are forming strategic partnerships to enhance product development and expand their market reach. Strategic partnerships involve companies leveraging each other's strengths and resources for mutual benefit. For example, in July 2023, Kedrion S.p.A., a US-based biopharmaceutical company, partnered with Kamada, an Israel-based biopharmaceutical company, to distribute KEDRAB (Rabies Immune Globulin [Human]) in the US. This collaboration has been key in co-developing and licensing the product while also raising awareness of rabies. The partnership helps protect individuals exposed to rabid animal bites from serious and potentially life-threatening conditions.

In December 2023, Kedrion Biopharma, an Italy-based biopharmaceutical company, signed a binding memorandum of understanding with Kamada Ltd. to extend and strengthen their collaboration for KEDRAB. This partnership aims to secure long-term supply, enhance commercial reach, and expand market opportunities in rabies prophylaxis. Kamada Ltd., based in Israel, specializes in plasma-derived protein therapeutics.

Major companies operating in the anti-rabies serum market are Merck & Co Inc., Sanofi SA, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, HCX Pharmaceuticals LLP, Intas Pharmaceuticals Ltd, Bavarian Nordic AS, Serum Institute of India Pvt Ltd., Bharat Serums And Vaccines Limited, Indian Immunologicals Ltd., Bharat Biotech., National Institute of Health Islamabad, ViNS Bioproducts Ltd., Shanghai Serum Bio-technology, Premium Serums and Vaccines Pvt Ltd., Congruent Pharmachem, Haffkine Bio Pharmaceutical Corporation Limited, LEXICARE PHARMA PVT. LTD., Avin Darou, Central Research Institute Kasauli, Vigilomed Pharmaceuticals.

North America was the largest region in the anti-rabies serum market in 2025. The regions covered in the anti-rabies serum market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anti-rabies serum market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the anti-rabies serum market by increasing costs of imported plasma-derived raw materials, biologics processing equipment, sterile packaging components, and cold-chain logistics systems used in immunoglobulin production and distribution. Hospitals and public health agencies in Asia-Pacific, Africa, and Latin America are most affected due to reliance on imported serums and limited domestic manufacturing capacity. These tariffs are increasing procurement costs and placing pressure on public healthcare budgets. However, they are also encouraging local plasma collection programs, regional biologics manufacturing investments, and improved supply chain resilience for essential rabies treatments.

The anti-rabies serum market research report is one of a series of new reports that provides anti-rabies serum market statistics, including anti-rabies serum industry global market size, regional shares, competitors with a anti-rabies serum market share, detailed anti-rabies serum market segments, market trends and opportunities, and any further data you may need to thrive in the anti-rabies serum industry. This anti-rabies serum market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anti-rabies serum, also known as rabies immune globulin (RIG), is a medical treatment used to provide immediate passive immunity against the rabies virus. It is typically administered to individuals who have been exposed to the virus through bites or scratches from potentially rabid animals, often alongside the rabies vaccine. The serum contains antibodies that neutralize the virus, helping to prevent the onset of rabies, which can be fatal once symptoms appear.

The main types of anti-rabies serum include human anti-rabies immunoglobulin and equine anti-rabies immunoglobulin. Human rabies immune globulin (HRIG) is derived from the blood plasma of human donors who have been immunized against rabies. It is preferred due to its reduced risk of allergic reactions and better compatibility with human patients. These serums are available in various dosage forms, including vials and prefilled syringes, and are administered via intravenous or intramuscular routes. They are used by a wide range of end-users, including hospitals, clinics, and veterinary hospitals.

The anti-rabies serum market consists of sales of rabies monoclonal antibodies, rabies immune globulin (RIG) combination products, and human rabies immune globulin (HRIG). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.